Objective: Analyses of longitudinal data pertaining to a single person can provide insight into the emotional dynamics of bipolar disorder at the symptom level. Aims were to examine (1) co-variation of a priori selected mental states in daily life in a patient with bipolar disorder; and (2) connections between these mental states during a hypomanic and a depressive period in bipolar disorder.
Methods:A single person diagnosed with bipolar disorder used the Experience Sampling Method (ESM) to collect data on experiences and mood ten times a day, for three months. Linear regression analyses were performed, stratified by hypomanic or depressive period. The a priori selected set of dependent variables included 'anxiety', 'down', 'cheerful', 'satisfied', 'tired' and 'lonely'. Independent variables were the same symptoms as collected one random moment earlier during the same day (t-1, lagged). Regression coefficients were presented in network graphs.
Results:Mood fluctuated strongly over time. The variable 'down' was central in the networks of both the hypomanic and depressive period. 'Satisfied' was only central in the hypomanic network.
Conclusion:In this patient, depression was the central emotion during both hypomanic and depressive periods. The distinction between depression and hypomania may sometimes lie in respectively the absence and presence of certain positive mood states. Furthermore, the present paper showed that extreme mood shifts in bipolar disorder can be studied after generating mood networks to gain precise insights in dynamic relations and the degree of cohesion between symptoms. These insights may be useful in the clinical setting to support self-monitored and personalised feedback and interventions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.